Real-world data on breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with proximal and terminal complement inhibitors.
Observational analysis identified risk factors for breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria, highlighting the role of complement inhibitors.
Key Points
Eighteen of eighty-seven patients with paroxysmal nocturnal hemoglobinuria experienced breakthrough hemolysis events.
The median decrease in hemoglobin for the overall cohort was 2.5 g/dL with significant LDH increases noted.
Analysis of patient records revealed that 71.42% of breakthrough hemolysis events were due to missed doses or infections.
Management strategies showed varied outcomes, reinforcing the importance of monitoring complement inhibitor adherence and infection risks.